These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Engerix-B, a new genetically engineered hepatitis B vaccine, approved by FDA. Oncology (Williston Park); 1989 Dec; 3(12):44. PubMed ID: 2534905 [No Abstract] [Full Text] [Related]
3. Vaccines: modern approaches and immunology. Kapil A Trop Gastroenterol; 1992; 13(4):164-7. PubMed ID: 1302389 [No Abstract] [Full Text] [Related]
4. Modern vaccines. Hepatitis. Eddleston A Lancet; 1990 May; 335(8698):1142-5. PubMed ID: 1971874 [No Abstract] [Full Text] [Related]
5. The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky's disease) eradication strategies. Mengeling WL; Brockmeier SL; Lager KM; Vorwald AC Vet Microbiol; 1997 Apr; 55(1-4):49-60. PubMed ID: 9220596 [TBL] [Abstract][Full Text] [Related]
6. DNA technology and vaccines. Brown F Int J Technol Assess Health Care; 1994; 10(4):583-91. PubMed ID: 7843880 [TBL] [Abstract][Full Text] [Related]
7. [Trends in the studies of the preparations of active and passive immunization. Bacterial vaccines]. Gałazka A Przegl Epidemiol; 1988; 42(4):317-31. PubMed ID: 3247475 [No Abstract] [Full Text] [Related]
8. British ruling supports legal challenge to broad patents. Dickson D Nature; 1996 Nov; 384(6604):7. PubMed ID: 8900258 [No Abstract] [Full Text] [Related]
9. The heritage of hepatitis B vaccine. Douglas RG JAMA; 1996 Dec; 276(22):1796-8. PubMed ID: 8946890 [TBL] [Abstract][Full Text] [Related]
10. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. André FE J Infect Dis; 1995 Mar; 171 Suppl 1():S33-9. PubMed ID: 7876646 [TBL] [Abstract][Full Text] [Related]
11. Genetic engineering applied to the development of vaccines. Murray K; Stahl S; Ashton-Rickardt PG Philos Trans R Soc Lond B Biol Sci; 1989 Aug; 324(1224):461-76. PubMed ID: 2573084 [TBL] [Abstract][Full Text] [Related]
13. Release potency tests of hepatitis vaccines. Descamps J; Mary A; Rommel E; Anhoury ML; De Neys R; Duchêne M Dev Biol Stand; 1999; 101():289-94. PubMed ID: 10566803 [TBL] [Abstract][Full Text] [Related]
14. [Vaccination against hepatitis virus B infection. Vaccine from inactivated HBsAg positive plasma or recombinant vaccine?]. Horejsí J Cas Lek Cesk; 1987 Jul; 126(31):981-2. PubMed ID: 2959363 [No Abstract] [Full Text] [Related]
15. Genetically engineered vaccines: problems and promises. Brown F; Dougan G; Snary D Microbiol Sci; 1984 Aug; 1(5):123-7. PubMed ID: 6444113 [TBL] [Abstract][Full Text] [Related]
16. [Antiviral vaccines]. Girard M Med Trop (Mars); 1999; 59(4 Pt 2):522-6. PubMed ID: 10901858 [TBL] [Abstract][Full Text] [Related]
17. Development of combined vaccines: manufacturers' viewpoint. André FE Biologicals; 1994 Dec; 22(4):317-21. PubMed ID: 7779355 [TBL] [Abstract][Full Text] [Related]
18. [Immunization against HIV. Problems in developing a vaccine]. Uhl D Med Monatsschr Pharm; 1988 Nov; 11(11):376-8. PubMed ID: 3059163 [No Abstract] [Full Text] [Related]
19. [Hepatitis A, B, C, ...: current developments]. Lavanchy D Rev Med Suisse Romande; 1991 Mar; 111(3):199-203. PubMed ID: 1827675 [No Abstract] [Full Text] [Related]